|
|
Evolus Inc (NASDAQ: EOLS) |
|
Price: $9.3400
$0.14 
1.522%
|
| Day's High:
| $9.43
| Week Perf:
| -1.48 %
|
| Day's Low: |
$ 9.22 |
30 Day Perf: |
-5.94 % |
| Volume (M): |
532 |
52 Wk High: |
$ 17.82 |
| Volume (M$): |
$ 4,972 |
52 Wk Avg: |
$12.80 |
| Open: |
$9.22 |
52 Wk Low: |
$8.67 |
|
|
| Market Capitalization (Millions $) |
595 |
| Shares
Outstanding (Millions) |
64 |
| Employees |
130 |
| Revenues (TTM) (Millions $) |
380 |
| Net Income (TTM) (Millions $) |
-56 |
| Cash Flow (TTM) (Millions $) |
-29 |
| Capital Exp. (TTM) (Millions $) |
6 |
Evolus Inc
Evolus Inc is a biotechnology and aesthetics company that is headquartered in Newport Beach, California. The company specializes in the development and commercialization of medical products that improve the appearance and well-being of individuals. Evolus Inc was founded in 2012 by a team of healthcare professionals and biotech industry veterans who had a vision of transforming the aesthetic industry through innovation.
One of Evolus Inc's flagship products is Jeuveau, a prescription medicine that is used to improve the appearance of frown lines between the eyebrows in adults. Jeuveau is a botulinum toxin type A injectable that works by blocking the nerve signals that cause muscles to contract. The treatment temporarily relaxes the muscles, thereby smoothing out the wrinkles and lines on the face. Jeuveau was approved by the US Food and Drug Administration (FDA) in 2019 and is the first new botulinum toxin approved for aesthetics in over a decade.
Evolus Inc is also actively engaged in the research and development of new medical products for aesthetics and other therapeutic areas. The company has a robust pipeline of programs in various stages of development, including biosimilars, topical formulations, and neurotoxins. Evolus Inc has a strong focus on using advanced technologies to improve the safety, efficacy, and convenience of its products.
In addition to its core operations, Evolus Inc is committed to advancing the aesthetics industry through education and collaboration. The company partners with healthcare providers and industry experts to advance best practices and promote patient safety. It also supports research initiatives that seek to better understand the science behind aging and aesthetics.
Evolus Inc is led by a team of seasoned executives with extensive experience in the biotech and aesthetics industries. The company is publicly traded on the NASDAQ stock exchange and has a global reach through its partnerships with distributors and healthcare providers. Evolus Inc has earned recognition for its innovative products, commitment to quality, and dedication to improving patient outcomes.
Company Address: 520 Newport Center Drive Suite 1200 Newport Beach 92660 CA
Company Phone Number: 284-4555 Stock Exchange / Ticker: NASDAQ EOLS
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Business Update
Published Wed, Jul 9 2025 1:18 PM UTC
Evolus Expands Global Footprint with Multifaceted Initiatives in Aesthetic Medicine NEWPORT BEACH, Calif. Evolus, Inc. (NASDAQ: EOLS), a distinguished player in the performance beauty sector, has made significant strides in expanding its global footprint. This progress is underscored by two pivotal developments: the introduction of Nuceiva (botulinum toxin type A) in Fra...
|
| Business Update
Published Tue, May 6 2025 8:12 AM UTC
In a decisive move to bolster its financial standing, Evolus Inc. (NASDAQ: EOLS), a Newport Beach-based performance beauty company, has announced the successful refinancing of its credit facilities, transitioning from a $125 million credit agreement to a substantial new $250 million facility with Pharmakon Advisors, LP. This strategic shift is set to not only strengthen Evol...
|
| Business Update
Published Fri, Mar 14 2025 2:52 AM UTC
Evolus: Achieving New Heights in Aesthetic Medicine A Look at 2024 Financials and Strategic Initiatives In a year marked by unprecedented growth and strategic advancements, Evolus, Inc. (NASDAQ: EOLS) shines as a beacon of success in the performance beauty industry. The Newport Beach-based company, which focuses on building a comprehensive aesthetic portfolio, recently an...
|
| Business Update
Published Tue, Jan 21 2025 3:26 PM UTC
Evolus Reports Record Preliminary Revenue Figures for Q4 and Full-Year 2024 Amid Market Underperformance Evolus, Inc. (NASDAQ: EOLS), headquartered in Newport Beach, California, has announced its preliminary, unaudited net revenue figures for the fourth quarter and the full year ending December 31, 2024. The company, which specializes in the aesthetic beauty sector, states t...
|
| Business Update
Published Thu, Oct 31 2024 6:36 PM UTC
Expanding Horizons in Aesthetic Medicine: The Regulatory Milestones of Evolus and the Launch of Estyme Injectable Hyaluronic Acid Gels In the burgeoning field of aesthetic medicine, regulatory advancements and innovative product offerings are paramount for market penetration and consumer trust. Recently, Evolus, Inc. a noteworthy player in performance beauty, announced crit...
|
| Per Share |
Current |
| Earnings (TTM) |
-0.89 $ |
| Revenues (TTM) |
5.97 $
|
| Cash Flow (TTM) |
- |
| Cash |
1.07 $
|
| Book Value |
-
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-0.89 $
|
| Revenues (TTM) |
5.97 $ |
| Cash Flow (TTM) |
- |
| Cash |
1.07 $
|
| Book Value |
- |
| Dividend (TTM) |
0 $ |
|
|
| |
| Reportable Segment |
|
 101.28 % |
of total Revenue |
| |
On January 21 2025 the Evolus Inc provided following guidance
nnEvolus Inc. Reports Preliminary Unaudited Financial Results for Q4 and Full-Year 2024, Setting New Revenue Milestonesnn
Evolus Inc. has released its preliminary financial estimates for the fourth quarter and the entirety of the fiscal year ending December 31, 2024. The disclosed figures demonstrate an impressive performance that not only meets but reaches the upper limits of the company's previously set guidance.
The company's announcement highlights that their net revenue results for both the fourth quarter and the full year are anticipated to be record-breaking. Unfortunately, specific numerical data regarding net revenue or detailed financial guidance figures have not been disclosed at...
|
|
|
